Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Parikh

Showing results (351-360 of 385) with videos related to

Pageof 39
Sort By:
The New England Journal of Medicine|September 23, 2021
Race, Genetic Ancestry, and Estimating Kidney Function in CKDChi-Yuan Hsu, Wei Yang, Rishi V Parikh, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 5, 2023
Influence of <i>CYP2C19</i>, <i>CYP2D6</i>, and <i>ABCB1</i> Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) StudyFarhana Islam, Leen Magarbeh, Samar S M Elsheikh, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 15, 2019
Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND reportNikita Nogovitsyn, Meghan Muller, Roberto Souza, et al.
Biological Psychiatry Global Open Science|June 12, 2025
High Baseline Plasma Anthranilic Acid Predicts Remission Upon Acute-Series Ketamine Infusion for Treatment-Resistant DepressionStephen A Murata, Zachary B Madaj, Colt D Capan, et al.
JAMA Psychiatry|February 11, 2026
One-Year Actigraphy Study of Sleep and Rest-Activity Rhythms as Markers of Relapse in DepressionAndre C Tonon, Adile Nexha, Jasmyn E A Cunningham, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|March 29, 2025
Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des résultats du traitement antidépresseur à l'aide des scores de risque polygéniques : Rapport sur l'étude CAN-BIND-1Leen Magarbeh, Samar S M Elsheikh, Farhana Islam, et al.
Psychoneuroendocrinology|July 6, 2021
Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study reportJee Su Suh, Laura M Fiori, Mohammad Ali, et al.
JAMA Network Open|January 4, 2020
Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With DepressionAndrey Zhdanov, Sravya Atluri, Willy Wong, et al.
Kidney International|August 22, 2024
An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working GroupCarla M Nester, David L Feldman, Richard Burwick, et al.
Elife|July 11, 2023
<i>SNORD90</i> induces glutamatergic signaling following treatment with monoaminergic antidepressantsRixing Lin, Aron Kos, Juan Pablo Lopez, et al.
Pageof 39

Showing results (351-360 of 385) with videos related to

Sort By:
Pageof 39
The New England Journal of Medicine|September 23, 2021
Race, Genetic Ancestry, and Estimating Kidney Function in CKDChi-Yuan Hsu, Wei Yang, Rishi V Parikh, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 5, 2023
Influence of <i>CYP2C19</i>, <i>CYP2D6</i>, and <i>ABCB1</i> Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) StudyFarhana Islam, Leen Magarbeh, Samar S M Elsheikh, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 15, 2019
Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND reportNikita Nogovitsyn, Meghan Muller, Roberto Souza, et al.
Biological Psychiatry Global Open Science|June 12, 2025
High Baseline Plasma Anthranilic Acid Predicts Remission Upon Acute-Series Ketamine Infusion for Treatment-Resistant DepressionStephen A Murata, Zachary B Madaj, Colt D Capan, et al.
JAMA Psychiatry|February 11, 2026
One-Year Actigraphy Study of Sleep and Rest-Activity Rhythms as Markers of Relapse in DepressionAndre C Tonon, Adile Nexha, Jasmyn E A Cunningham, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|March 29, 2025
Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des résultats du traitement antidépresseur à l'aide des scores de risque polygéniques : Rapport sur l'étude CAN-BIND-1Leen Magarbeh, Samar S M Elsheikh, Farhana Islam, et al.
Psychoneuroendocrinology|July 6, 2021
Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study reportJee Su Suh, Laura M Fiori, Mohammad Ali, et al.
JAMA Network Open|January 4, 2020
Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With DepressionAndrey Zhdanov, Sravya Atluri, Willy Wong, et al.
Kidney International|August 22, 2024
An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working GroupCarla M Nester, David L Feldman, Richard Burwick, et al.
Elife|July 11, 2023
<i>SNORD90</i> induces glutamatergic signaling following treatment with monoaminergic antidepressantsRixing Lin, Aron Kos, Juan Pablo Lopez, et al.
Pageof 39